Nivolumab
Renal Pelvis/Ureter Urothelial Carcinoma
Explore 17 assets in Renal Pelvis/Ureter Urothelial Carcinoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Nagoya University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06983210CT.gov Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma | — | Recruiting | — | — | — |
NCT04953104CT.gov ARID1A and/or KDM6A Mutation and CXCL13 Expression | — | Active Not Recruiting | — | — | — |
NCT03606174CT.gov A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma | — | Terminated | — | — | — |
NCT02496208CT.gov Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Pelvis/Ureter Urothelial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Nagoya University | P2 | B · 60 |
| Carboplatin | Cardiff University | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | Nagoya University | P3 | BBB |
| Vinblastine | University of Southern California | P3 | BBB |
| Nivestim | Tulane University Health Sciences Center | P2 | BBB |
| Adriamycin | University of Southern California | P3 | BBB |
| Isocyclophosphamide | Tulane University Health Sciences Center | P2 | BB |
| Methotrexate | University of Southern California | P3 | BB |
| Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) | National Cancer Institute (NCI) | P2 | BB |
+41 more in the Renal Pelvis/Ureter Urothelial Carcinoma cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Renal Pelvis/Ureter Urothelial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-renal-pelvisureter-urothelial-carcinoma-47710
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →